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Aggregates of the microtubule-associated protein Tau are neuropathological hallmark lesions in Alzheimer’s disease (AD) and
related primary tauopathies. In addition, Tau is genetically implicated in a number of human neurodegenerative disorders
including frontotemporal dementia (FTD) and Parkinson’s disease (PD). The exact mechanism by which Tau exerts its
neurotoxicity is incompletely understood. Here, we give an overview of how studies using the genetic model organism Drosophila
over the past decade have contributed to the molecular understanding of Tau neurotoxicity. We compare the diﬀerent available
readouts for Tau neurotoxicity in flies and review the molecular pathways in which Tau has been implicated. Finally, we emphasize
that the integration of genome-wide approaches in human or mice with high-throughput genetic validation in Drosophila is a
fruitful approach.
1. Introduction
For more than a century, the fruit fly Drosophila has been
used to unravel major biological questions. The fruit fly
has played crucial roles in deciphering various develop-
mental signaling cascades such as the Notch, Wingless, and
Hedgehog pathways. In addition, studies using Drosophila
have contributed to a wide range of topics in neurobiology
including neurodevelopment, behavior, circadian rhythms,
learning and memory, synaptic transmission, and neurode-
generation [1, 2]. Since most basic molecular and cell
biological mechanisms are conserved between humans and
Drosophila and since ∼70% of all human disease genes
have an evolutionary conserved fly homolog, studies in flies
have also provided valuable insights into the biology of
human disease [3]. During the last decade, Drosophila has
gained attention as a model system for common human
neurodegenerative brain disorders [4]. In general, these
models are based on the misexpression of human proteins
such as α-synuclein [5], Tau [6, 7], and TDP-43 [8] that
are present in the neuropathological hallmark lesions of
patients with Parkinson’s disease (PD), Alzheimer’s disease
(AD), frontotemporal dementia (FTD), and amyotrophic
lateral sclerosis. Interestingly, expression of these proteins in
flies results in neurotoxicity and the underlying molecular
mechanisms appear to be largely protein- or disease-specific
suggesting that this approach is useful.
Here, we review the contribution of Drosophila to the
molecular understanding of Tau neurotoxicity, a central
player in the AD-FTD spectrum of disorders [9]. We give a
brief overview of the most commonly used genetic tools in
Drosophila and summarize the diﬀerent available Taumodels
and readouts for Tau neurotoxicity. Together, these studies
paint a multifaceted picture of Tau being involved in a wide
range of biological processes and highlight the complex role
of Tau phosphorylation in mediating its toxicity.
2. Modeling Tauopathy in Drosophila
2.1. The Drosophila Genetic Toolkit in a Nutshell. Next to
the fact that the fundamental molecular and cell biological
aspects of neuronal biology are conserved between human
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and Drosophila, the main advantage of the fly is its powerful,
flexible, and extensive genetic toolkit. It essentially allows the
expression, downregulation, or mutation of any gene, in a
tissue- and time-specific manner [10].
A major tool is the binary GAL4-UAS system, which
allows the expression of a genetic responder construct down-
stream of an Upstream Activator Sequence (UAS) driven by
tissue-specific expression of the yeast GAL4 transcription
factor [11]. The system can be used to either silence a
gene using an RNAi-construct or to induce mis- and/or
overexpression using a cDNA construct. Many driver lines
have been generated, in which promoters of genes have
been inserted upstream of the GAL4 sequence. The diversity
of gene promoters makes it possible to target nearly all
tissue or cell types. However, they usually do not allow time
specificity. The most commonly used GAL4 drivers induce
expression of the target protein from early developmental
stages. Restricting expression to adulthood or to a defined
time is relevant when modeling late-onset degeneration. For
this reason, modifications of the GAL4-UAS system were
developed in Drosophila and allow a tight regulation of
transgene expression. For example, the TARGET system uses
a temperature-sensitive mutant of the yeast GAL4 repressor
GAL80 [12]. GAL80ts is active at low temperatures and
suppresses GAL4 activity. To activate GAL4-induced gene
expression in adulthood, adult flies are moved to 30◦C,
a temperature at which GAL80ts becomes inactivated and
no longer inhibits GAL4 activity. In addition expression is
reversible and shut oﬀ when shifting the flies back to lower
temperature. Another system of conditional gene expression
in Drosophila is called the Geneswitch system [13]. It
consists of the pharmacological activation of a RU486-
sensitive GAL4-derived transcription activator. The yeast
GAL4 DNA binding domain has been fused with a mutated
human progesterone receptor-ligand binding domain and
with the transcriptional activation domain of the human
p65, a member of the NFkB family [14]. The chimeric fusion
protein is activated by RU486, binds to UAS sequences, and
activates the transcription of downstream sequences. For
RU486 induction, RU486 is added to Drosophila food [13].
Among the other genetic tools of Drosophila are trans-
posons, which are mobile genetic elements, in which the
transposase has been replaced by other sequences, such
as UAS sequences to generate enhancer traps and GFP
sequence that can be spliced to generate protein traps for
example [10]. The main advantage is that these elements
can be easily mobilized and insert randomly in the genome.
If the transposon disrupts the gene sequence in which it
is inserted, it can generate loss-of-function alleles of the
gene. The imprecise excision of the transposon can also
be used to generate genomic null mutations [10]. Diﬀerent
transposons such as P-element, PiggyBac, or Minos elements
with complementary bias in their insertion site are now
used to cover the whole Drosophila genome [15]. Null
alleles can also be generated by chemical mutagenesis or
X-ray radiation. Other powerful techniques are based on
mitotic recombination, which can be used in a controlled
manner to generate homozygous-mutant tissue in a het-
erozygous background. This allows determining the function
of developmentally lethal genes in adult tissues [16]. All these
tools give to researchers using Drosophila the possibility to
perform in-depth reverse genetic studies as well as large-scale
forward genetic screens, enabling the identification of novel
biological pathways in an unbiased manner [17].
2.2. Tau Genetic Reagents. At least 37 constructs have
been used to generate transgenic Drosophila Tau strains
(Table 1). Tau cDNAs are most frequently inserted down-
stream of a UAS promoter although some Tau cDNAs
are inserted downstream of the eye-specific gl promoter
enabling simultaneous and independent expression of other
UAS-constructs [7]. Tau transgenes were first used to
improve neuronal labeling in morphological studies [18–20]
until Williams and coworkers showed that these constructs
induce neurodegeneration characterized by axonal loss and
swellings [21]. Many Drosophila models were then generated
using human Tau (hTau) (Table 1). Some are based on 0N3R,
0N4R, and 2N4R wild-type hTau isoforms [6, 7, 21], whereas
others express mutated forms hTau, that cause autosomal
dominant Tau-positive FTD, such as hTauR406W, hTauV337M,
and hTauP301L [6, 22]. To explore specific mechanisms
of hTau toxicity or dysfunction, transgenes with targeted
mutations and truncations were also generated, including
constructs which abolish or mimic hTau phosphorylation or
proteolytic cleavage [23–31]. Together, these models explore
the great diversity of tauopathies.
While most Drosophila studies on Tau neurotoxicity are
based on overexpression of hTau, it is important to mention
that Drosophila has a single tau gene/protein (dTau) [36].
Compared to the 6 human isoforms, which harbor either
3 or 4 C-terminal microtubule-binding domains (MTBD)
and 0 to 2 N-terminal insertions, the dTau protein contains
5 MTBD with 46% identity and 66% similarity to the cor-
responding hTau region but no N-terminal insertions [36].
Homozygous dTau null Drosophila mutants are viable and
fertile and display no obvious morphological or behavioral
defects [33], although a microtubule-based defect in polarity
has been shown in dTau null oocytes [37]. The absence
of major defects in dTau null mutants may be due to
redundancy with other microtubule-associated proteins such
as Futsch, the MAP1B Drosophila ortholog. In agreement,
the degenerative phenotype of hypomorphic futsch alleles
was partially suppressed by dTau overexpression in the
central nervous system [38]. Some constructs also express
dTau, which have been used to compare the function and
toxicity of endogenous dTau with hTau [32–34, 39]. These
studies revealed similar degrees of neuronal dysfunction for
dTau and hTau (see below) although genetic and physical
interaction partners showed important diﬀerences between
the two Tau proteins [39, 40].
2.3. Readouts of Tau Neurotoxicity and Dysfunction in Dro-
sophila. The choice of a readout for Tau neurotoxicity or
dysfunction results from a trade-oﬀ between the ease and
speed of scoring a phenotype and its biological or pathogenic
relevance. The Drosophila exoskeleton provides a wealth of
external features, such as bristles and compound eyes, which
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Table 1: Tau constructs available in Drosophila.
Constructs Type Origin
Drosophila constructs
UAS-dTau Wild-type Mershin et al. 2004 [32]
UASp-dTauA:mGFP6 Fusion Doerflinger et al. 2003 [33]
UAS-dTau:1D4 Tagged form Feuillette et al. 2010 [34]
Bovine constructs
UAS-bTau Wild-type Ito et al. 1997 [18]
bTau1–382:GFP Fusion Micklem et al. 1997 [35]
UAS-bTau:GFP Fusion Murray et al. 1998 [19]
UAS-bTau:lacZ Fusion Callahan and Thomas 1994 [20]
Human 0N3R construct
UAS-hTau Williams et al. 2000 [21]
Human 2N4R constructs
gl-hTau Wild-type Jackson et al. 2002 [7]
gl-hTauP301L FTDP17 mutation Karsten et al. 2006 [22]
UAS-hTau Chatterjee et al. 2009 [23]
gl-hTauS2A (S262A/S356A) Phospho-deficient Chatterjee et al. 2009 [23]
UAS-hTauS2A (S262A/S356A) Phospho-deficient Chatterjee et al. 2009 [23]
gl-hTauS11A
(S46A/T50A/S199A/S202A/
S205A/T212A/ S214A/T231A/ Phospho-deficient Chatterjee et al. 2009 [23]
S235A/S396A/S404A)
UAS-hTauS11A
(S46A/T50A/S199A/S202A/
S205A/T212A/S214A/T231A/ Phospho-deficient Chatterjee et al. 2009 [23]
S235A/S396A/S404A)
UAS-hTau:FLAG Tagged form Kosmidis et al. 2010 [24]
UAS-hTauSTA:FLAG
(S238A/T245A)
Tagged form Phospho-deficient Kosmidis et al. 2010 [24]
Human 0N4R constructs
UAS-hTau Wild-type Wittmann et al. 2001 [6]
UAS-hTauV337M FTDP17 mutation Wittmann et al. 2001 [6]
UAS-hTauR406W FTDP17 mutation Wittmann et al. 2001 [6]
UAS-hTauR406W S2A (S262A/S356A) FTDP17 mutation Phospho-deficient Nishimura et al. 2004 [25]
UAS-hTauR406W S202A FTDP17 mutation Phospho-deficient Nishimura et al. 2004 [25]
UAS-hTauT111A/T153A Phospho-deficient Steinhilb et al. 2007 MBC [26]
UAS-hTauT175A/T181A Phospho-deficient Steinhilb et al. 2007 MBC [26]
UAS-hTauT199A/T217A Phospho-deficient Steinhilb et al. 2007 MBC [26]
UAS-hTauS202A/S205A Phospho-deficient Steinhilb et al. 2007 MBC [26]
UAS-hTauT212A Phospho-deficient Steinhilb et al. 2007 MBC [26]
UAS-hTauS214A Phospho-deficient Steinhilb et al. 2007 MBC [26]
UAS-hTauT231A/S235A Phospho-deficient Steinhilb et al. 2007 MBC [26]
UAS-hTauS262A Phospho-deficient Iijima-Ando et al. 2010 [28]
UAS-hTauS396A/S404A Phospho-deficient Steinhilb et al. 2007 MBC [26]
UAS-hTauS422A Phospho-deficient Steinhilb et al. 2007 MBC [26]
UAS-hTauAP5
(S202A/S205A/T212A/ Phospho-deficient Steinhilb et al. 2007 MBC [26]
T231A/S235A)
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Table 1: Continued.
Constructs Type Origin
UAS-hTauAP
(T111A/T153A/T175A/T181A/
S199A/S202A/S205A/T212A/ Phospho-deficient Steinhilb et al. 2007 JNR [26]
S214A/T217A/T231A/S235A/
S396A/S404A/S422A)
UAS-hTauE14
(T111E/T153E/T175E/T181E/
S199E/S202E/S205E/ T212E/ Phosphomimetic Khurana et al. 2006 [29]
T217E/T231E/S235E/S396E/
S404E/S422E)
UAS-hTauK44Q/R230Q Calpain-resistant Reinecke et al. 2011 [30]
UAS-hTau44–230 Calpain 17kDA proteolytic fragment Reinecke et al. 2011 [30]
UAST-hTau1–421 C-terminally truncated Tau Khurana et al. 2010 [31]
Table 2: Readouts of Tau toxicity in Drosophila.
Organ/Tissue/Cells Phenotypes Promoters/Drivers
Eye
Roughness GMR
Photoreceptor cell
viability
Gl
Sev
Notum Loss of bristles Eq
Nervous system
Lethality Elav
Shortened lifespan Appl
Brain vacuolisation Repo
TUNEL positive cells Gl
Activated caspase3
positive cells
C472
Loss of olfactory
Learning and memory
C772
Motor neurons
Axonal transport defects D42
Locomotor deficits OK6
“juvenile” phenotype:
loss of wing
Elav
expansion and cuticle
tanning
Burs12
Appl
can be aﬀected by genetic manipulations, and for which the
resulting phenotypes can be scored simply and quickly in
young flies by looking through a stereomicroscope. These
readouts of neurotoxicity or dysfunction, especially the eye
external morphology, have been successfully used in screens
for modifiers of Tau pathology and other neurodegenerative
diseases [41–43]. Here we give an overview of the diﬀerent
available readouts of Tau neurotoxicity and dysfunction in
Drosophila (Table 2).
2.3.1. The Eye. Roughening of the eye is the most commonly
used external phenotype to evaluate toxicity of neurodegen-
erative proteins, including Tau, in Drosophila. The fly eye
consists of around 800 highly regularly implanted omma-
tidia, each containing 8 photoreceptor neurons. The eye is an
excellent tissue to study the eﬀect of organismal lethal genes
as it is dispensable for viability. Due to its repetitive crystal-
like pattern, it is ideal to identifymild external morphological
defects upon expression of human neurotoxic proteins. It
thus constitutes a genetically sensitized system that allows the
identification of genetic modifiers by assessing roughening
of the eye as a quantitative readout of neurotoxicity. The
eye surface of the Drosophila eye is generated during the
final stages of development and thus, this phenotype has
a developmental component. However, it is associated with
vacuolization in the underlying optic brain structures [7],
a typical sign of degeneration in the fly nervous system.
Interestingly, a pure degenerative phenotype can be estab-
lished in the Drosophila eye by assessing the viability of
photoreceptor neurons over time in living adult flies. This
is possible thanks to the cornea neutralization technique,
which consists of visualizing photoreceptor neurons directly
through the cornea of a living anesthetized fly, immersed
in a medium with a refractive index comparable to the
fly cornea, such as water [44]. Photoreceptor neurons are
detected based on Rhodopsin autofluorescence or on the
expression of fluorescent protein such as GFP. Because it is
an in vivo method, the same fly can be analyzed at several
time points during adult lifespan and exhibit progressive
degeneration. The usefulness of related fluorescence-based
techniques in neuronal degeneration was further illustrated
by Gambis, and colleagues [45]. In a clonal screen using
a derived method, called Tomato/GFP-FLP/FRT method,
several mutants were identified that induced progressive
photoreceptor loss. These methods have not yet been tested
in the context of Tau neurotoxicity or other proteinopathies.
Another potentially useful method that has not yet been used
in Drosophila models of Tauopathies is the electrophysiolog-
ical analysis using electroretinogram recordings (ERG). ERG
analysis consists of recording the electrophysiological activity
of the retina upon exposure to light. This activity is sensitive
to PR degeneration. ERGmeasurements can be used to show
a progressive loss of neuronal functioning [46].
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2.3.2. The Notal Bristles. Neurotoxicity assays based on ex-
ternal fly features, such as eye roughness, are important as
they are easily scorable and thus suited for high-throughput
genetic screening. Interestingly, a novel bristle loss pheno-
typic assay for Tau neurotoxicity was described recently [47].
The Drosophila notum (part of the thorax) harbors around
200 bristles, which are sensory organs, connected at the
base with the dendrite of a sensory neuron. Overexpression
of diﬀerent variants of hTau in the notum using the
notum-specific Eq-GAL4 driver leads to bristle loss. hTau
toxicity can be quantified by simply counting the bristles.
This was done for wildtype hTau, phosphomutant hTau,
and phosphomimetic hTau in addition to FTD-associated
mutant hTau. In general, the sensitivity of the eye and
the bristles to diﬀerent variants was comparable. The notal
bristle assay thus constitutes an interesting complementary
and quantitative model to molecularly dissect Tau neurotox-
icity.
2.3.3. Lifespan and Lethality. The ultimate consequence of
(neuro)toxicity is the death of the whole organism, which
can also be scored relatively easily by counting the number
of surviving flies over time. Depending on the rearing
conditions, wild-type flies live around 60 to 80 days and
lifespan can be easily used as a quantifiable readout of Tau
toxicity [6, 31, 47–50]. On the other hand, lethality can occur
during development before eclosion of adult flies. Using
the pan-neuronal Appl-GAL4 and Elav-GAL4 drivers, Tau-
expressing flies exhibited pupal lethality, which can also be
quantified and serve as a readout of Tau toxicity [49, 51, 52].
2.3.4. Brain Degeneration. Neuronal degeneration in
Drosophila can be demonstrated by the presence of vacuoles
in brain tissue using histological and immunohistochemical
methods. Interestingly, vacuoles are found in the brains of
hTau-expressing flies [6, 7, 32] and, although labor-intensive,
the number of vacuoles can be used as a quantitative readout
of hTau neurotoxicity [29, 53, 54]. Neuronal cell death can
be further detected using specific stainings. The TUNEL
technique is frequently used to detect apoptosis in brains
of hTau-expressing flies [25, 29, 50, 54]. Alternatively,
immunostaining of activated cleaved caspase-3 can be
performed to demonstrate apoptotic cell death [50, 53].
2.3.5. Axonal Transport Assays. The main function of Tau is
to bind to microtubules. Hence, it has been hypothesized
that Tau toxicity or dysfunction could result from a defect
in axonal transport. Drosophila is well suited to study axonal
transport because fluorescent (GFP) fusion proteins tagging
transport vesicles can be expressed in larval motor neurons,
which are accessible for imaging in living intact animals
[55]. In addition, larval locomotor phenotypes have been
described for mutants that aﬀect axonal transport, such
as kinesin or dynein mutants [56, 57]. Immunostainings
against Synaptotagmin were first performed to assess axonal
transport in Appl-GAL4 larvae expressing hTau [51, 52]. It
enables the visualization of synaptic vesicles along axons.
Mudher and colleagues then used a GFP/neuropeptideY
fusion protein to image vesicle axonal transport through the
body wall of living larva expressing hTau in motor neurons
(D42-GAL4 driver) [40, 48, 55]. Talmat-Amar and colleagues
further enriched the analysis with a Synaptotagmin-GFP
construct expressed in larval motor neurons (OK6-GAL4
driver) and with kymographs [49]. Kymographs consist of
visualizing the movements of all vesicles within a nerve
segment over time. They allow the measurement of the
kinetic parameters of vesicular movement such as instant
velocity or pausing time.
Axonal transport disruption can also be detected at the
level of the whole organism. Two readouts, locomotor deficits
and the “juvenile” phenotype, have been used depending
on the neurons in which hTau is expressed. First, Mudher
and colleagues analyzed successfully the motor function of
larvae expressing hTau in motor neurons (D42-GAL4) using
contraction, crawling, line-crossing, and righting assays [55].
These assays enabled them to compare the eﬀects of 3R hTau
and dTau on locomotor functions or the interaction between
hTau and Aβ42 [40, 48]. Locomotor functions can also be
assessed in adult flies using a climbing or negative geotaxis
assay. Flies display a strong negative geotactic response.
When tapped to the bottom of a vial they rapidly climb to
the top of the vial, and most flies remain there. Locomotor
dysfunction impairs climbing ability. Using this readout,
locomotor dysfunction was quantified in Tau-expressing flies
(D42-GAL4 and elav-GAL4) [53, 55]. Second, a strong defect
in axonal transport can also result in altered release of neu-
ropeptides or neurohormones at neurohemal release sites.
When bursicon neurons are aﬀected, loss of the bursicon
neurohormone prevents wing expansion and cuticle tanning
just after fly eclosion [58]. This immature unexpanded wing
phenotype is easily visible and quantifiable in young flies.
Several drivers, OK6-GAL4, Burs12-GAL4, Appl-GAL4 or
elav-GAL4, are expressed in bursicon neurons [51, 59, 60],
and it has been shown that the inhibition of axonal transport
per se in bursicon neurons aﬀects wing expansion [49]. This
phenotype has been used as a readout to compare the toxicity
of phosphorylation mutants of hTau and to show a genetic
interaction between hTau and Appl, the fly APP homolog
[49, 51].
2.3.6. Learning andMemory Assays andMushroom Body Abla-
tion Phenotypes. Tauopathies aﬀect the cognitive functions
of patients. InDrosophila, olfactory memory can be used as a
readout for assessing impaired cognitive functions in hTau-
expressing flies. Olfactory learning and memory relies on
neurons located in a distinct region of the fly brain called
mushroom bodies [61]. Tau expression can be targeted to
these neurons using the pan-neuronal driver elav-GAL4 or
the late pupal, adult mushroom body-specific drivers C492-
GAL4, C772-GAL4 [24, 32]. By testing response to attractive
and repulsive odors, olfactory learning andmemory has been
standardized and can be measured in transgenic flies. An
aversive phototaxis suppression assay has also been used to
measure learning and memory function in Tau-expressing
flies [32, 53]. Strikingly, pan-neuronal overexpression of
hTau leads to selective and nearly complete ablation of
the mushroom bodies [24, 32]. These phenotypes can
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also be used to identify genetic interactors of Tau dys-
function/toxicity.
3. Pathogenic Mechanisms of Tauopathies
3.1. Tau and Phosphorylation. Studies in Drosophila have re-
vealed a highly complex role of Tau phosphorylation in
mediating neuronal function or toxicity. The rough eye
phenotype was the starting point for the Jackson lab, to
investigate the role ofWingless signaling and Shaggy (Sgg, the
fly GSK3β homolog) on hTau toxicity [7]. Overexpression of
Sgg significantly enhanced hTau toxicity, even to the point
that neurofibrillary tangle-like structures could be detected,
while a loss-of-function allele of Sgg had a beneficial eﬀect on
toxicity. In order to investigate if hTau toxicity is mediated
by Wingless signaling, genetic interaction between Tau
and the downstream Sgg target armadillo (arm), which is
inhibited by Sgg, was investigated. Unexpectedly, loss of arm
rescued whereas misexpression enhanced the hTau rough eye
phenotype independently of hTau phosphorylation. These
results suggested that the Sgg interaction with hTau does
not go through the canonical Wnt pathway and that Sgg
directly or indirectly leads to phosphorylation of hTau (see
also Section 3.5.1). A follow-up study further suggested an
indirect eﬀect since the mutant 2N4R hTauS11A that cannot
be phosphorylated by Sgg is still toxic [23].
The role of phosphorylation in Tau pathology was
investigated by several labs [23, 25–27, 49, 62]. The Lu lab
showed that, overexpression of fly PAR-1 kinase (MARK)
in the eye induces a moderate eye phenotype, which was
partially suppressed in a heterozygous deletion background
of dTau. A strong synergistic enhancing eﬀect was observed
in a background expressing hTauR406W [25]. Reduction of
PAR-1 function or mutation of PAR-1 phosphorylation
sites (S2A) was shown to reduce 0N4R hTauR406W toxicity.
Phosphorylation was also suggested to occur in a structurally
ordered pattern. First S262 and S356 are phosphorylated
which facilitates targets of Sgg to be phosphorylated. The
Jackson lab independently showed that wild-type 2N4R
hTau, in which serines S262 and S356 are substituted to
alanines (S2A), displayed lower toxicity in the eye due to
the inability of PAR-1 to phosphorylate the S2A tau at the
two mutated serines [48]. However, the Lu and Jackson labs
disagree about the priming eﬀect of PAR-1 before Sgg phos-
phorylation. The Lu lab showed that the 0N4R hTauR406W/S2A
construct is not phosphorylated at some Sgg sites and is
refractory to toxic enhancement by Sgg overexpression [25],
while the Jackson lab found that 2N4R hTauS2A, although
less toxic, was still phosphorylated at Sgg sites when Sgg
is overexpressed [23]. The diﬀerent conclusions by the two
labs are unclear but may be due to the diﬀerent isoforms
used (0N4R hTauR406W/S2A versus 2N4RhTauS2A). Altogether,
these results demonstrate, in contrast to Sgg, a direct role for
PAR-1 in mediating Tau toxicity.
In order to identify phosphorylation sites involved in
toxicity, the Feany lab generated a number of 0N4R hTau
constructs each having one or two Ser-Pro and/or Thr-
Pro mutated to phosphoresistant alanines (Table 1) [27].
Although no significant reduction in toxicity was observed
for any of these phospho-deficient constructs, a 0N4R hTau
construct in which 14 Ser-Pro and Thr-Pro target sites are
mutated to alanine (hTauAP) displayed reduced neurotoxicity
[26]. Accordingly, a phosphomimetic construct with the
same 14 epitopes mutated to glutamate (hTauE14) increased
Tau toxicity, suggesting that toxicity relies on cooperation
of diﬀerent phosphorylation sites. However, using a 2N4R
construct in which 11 Ser-Pro and Thr-Pro target sites are
mutated to alanine (hTauS11A) of which 9 overlapped with
hTauAP, the Jackson lab did not observe decreased toxicity in
the eye [23]. The reasons for these discrepancies are not clear
but might be related to the diﬀerent hTau isoforms used, the
number of mutated sites, or the diﬀerences in the mutated
sites. The toxicity of the phosphomimetic TauE14 construct
has been further reported in mushroom body neuroblasts,
whereas the phospho-deficient TauAP, 0N4R hTauR406W/S2A,
and 2N4R hTauS2A were not toxic [24]. In mushroom body
neuroblasts, Ser238 and Thr245 were also shown to be
essential for 2N4R hTau toxicity [24].
Tau phosphorylation also aﬀects neuronal function in the
absence of neuronal loss/toxicity. The tau protein is known
best, functionally, as a microtubule stabilizing protein. The
fraction of Tau that is bound to microtubules is inversely
correlated with its phosphorylation state. In the context
of microtubule stabilization, hyperphosphorylation leads to
loss-of-function eﬀects while hypophosphorylation can lead
to increased microtubule stabilization. How expression of
hyperphosphorylated hTau aﬀects microtubular integrity in
the fly was elegantly investigated by the Mudher group
[55, 63]. They found that, despite the presence of endo-
geneous dTau, overexpression of 0N3R hTau led to axonal
microtubule breakdown. When expressed in flies, 0N3R
hTau becomes hyperphosphorylated. Upon treatment with
Li+, a GSK3β inhibitor, phosphorylation was reduced and
microtubule binding of hTau was increased. Interestingly, the
same was shown for dTau, suggesting that hyperphosphory-
lated hTau can sequester endogeneous dTau. Furthermore, it
was shown that the physical interaction between dTau and
hTau occurred in a phosphorylation-dependent manner. In
addition, the Mudher lab found that overexpression of hTau
in motorneurons leads to defects in axonal transport without
neurodegeneration. They investigated the role of hTau
phosphorylation by Sgg on axonal transport. Pharmacologic
inhibition of Sgg, with two diﬀerent inhibitors, could reverse
Tau-induced defects in axonal transport. Overexpression of
hTau resistant to Sgg phosphorylation (TauS11A) was later
shown to display a higher binding aﬃnity for microtubules
[23]. This suggests that pharmacologic inhibition of Sgg
probably restores axonal transport by increasing the micro-
tubule aﬃnity of hTau. Later, Talmat-Amar and coworkers
showed that at the level of axonal transport, hTauAP was
clearly more toxic than hTauWT or hTauE14 and related to its
capacity to bind more strongly to microtubules [49]. Taken
together, these data suggest that microtubule aﬃnity of hTau
is most likely, at least in part, regulated by Sgg-dependent
phosphorylation. Furthermore, it can be concluded that both
hypo- and hyperstabilization of axonal microtubules has
detrimental eﬀects.
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3.2. Tau and the Cytoskeleton
3.2.1. Binding of Tau to Microtubules. By nature, Tau is a
microtubule-binding protein and therefore has a strong
involvement in the regulation of the cytoskeleton. In Dro-
sophila, endogenous dTau and exogenous bTau and hTau
colocalize with microtubules in vivo [33, 35, 36]. dTau and
hTau interact with microtubules in microtubule cosedimen-
tation assays in vitro [23, 33]. dTau binds microtubules
more strongly than 0N4R hTau or hTauR406W and hTauV337M
[34]. This weak binding of hTau to microtubules depends
on its phosphorylation status. The microtubule-bound
hTau in the pellet was found to be hypophosphorylated,
whereas hTau in the supernatant was phosphorylated [34].
In addition, using phosphomimetic and phospho-deficient
hTau forms to assess the role of phosphorylation, it was
shown that the majority of phospho-deficient hTauAP and
hTauS11A proteins were pelleted with microtubules, whereas
the pseudophosphorylated TauE14 proteins remained mostly
in the supernatant fraction [23, 34, 49]. Thus hTau expressed
in Drosophila is phosphorylated, which prevents a strong
binding to microtubules.
3.2.2. Functional Consequences of Deregulated Tau-Micro-
tubule Interaction. One functional consequence of Tau
deregulation is the alteration of the microtubule network.
Overexpression of hTau has been associated with micro-
tubule breakdown in peripheral nerves of L3 larvae [63].
In this model, the cytosolic phosphorylated hTau bound
endogenous dTau and dissociated dTau from microtubules.
This would be responsible for the disruption of the micro-
tubule cytoskeleton as claimed by the Tau-microtubule
hypothesis [64]. In loss-of-function experiments, both fol-
licle and germline cells of dTau null ovaries did not display
strong alterations in their microtubule network [33]. How-
ever, the polarity of dTau null oocytes was altered at stage 10,
a phenotype similar to that of excessive PAR-1 overexpression
[37]. In addition, dTau overexpression partially rescued the
phenotype of PAR-1 overexpression, which suggests that
dTau is involved in maintaining microtubule stability in the
oocyte and that PAR-1 regulates oocyte polarity at least partly
through dTau [37].
Another functional consequence of Tau deregulation is
the alteration of axonal transport. Overexpression of bTau,
0N3R hTau, and dTau in third instar larvae results in large
accumulations of synaptotagmin or GFP:neuropeptideY-
tagged vesicles in motor neuron axons [40, 51, 55].
Coexpression of GSK3β and pharmacological inhibition of
GSK3β, respectively, increased and decreased this phenotype,
suggesting that Tau phosphorylation could enhance axonal
transport disruption [55]. Although this study did not detect
a vesicle motion defect, a later study also using 0N4R hTau
showed an increase in the pausing rate of the vesicles within
axons [49]. The pausing defect was drastically stronger
using 0N4R hTauAP, a phospho-deficient form that strongly
binds to microtubules and aﬀected mainly anterograde
transport. Expression of hTauAP induced a juvenile wing
inflation phenotype, similarly as downregulation of dynein
and kinesin [49]. Expression of the pseudophosphorylated
hTauE14 did not disrupt vesicle motion and even slightly
increased instant velocity [49]. Interestingly, a reciprocal
regulation of Tau phosphorylation by axonal transport has
been described [52]. A nonlethal reduction in kinesin-1-
dependent axonal transport was associated with increased
activated cJun N-terminal Kinase (JNK), hTau phospho-
rylation, hTau accumulation, axonal vesicle accumulation,
and hTau toxicity [52]. This suggested that axonal transport
defects can activate axonal stress kinase pathways leading
to hTau phosphorylation, stabilization, and an increase in
hTau-mediated neurodegeneration.
Taken together, these studies seem to converge on the
notion that direct PAR-1-mediated Tau phosphorylation
is directly involved in neurotoxicity, while the eﬀects of
GSK3β appear to be more indirect and related to neuronal
functioning rather than toxicity.
3.2.3. Tau and the Actin Cytoskeleton. cheerio (fly ortholog
of filamin), chd64 (fly ortholog of transgelin-3), jaguar
(fly ortholog of myosinVI), paxillin, 4 regulators of the
actin network, were identified as modifiers of the TauV337M-
mediated rough eye phenotype in a misexpression screen
[43]. cheerio had been identified also in a previous similar
screen [41]. Filamin-A and MyosinVI were further found to
colocalize with fibrillary hTau protein in AD and FTD brains
[65]. The Feany lab showed that actin might be a critical
mediator of Tau-induced neurotoxicity [66]. They showed
that hTauR406W interacts directly with F-actin in the fly
brain. hTauR406W overexpression induced the accumulation
of F-actin and the formation of actin-rich rods, which were
similar to Hirano bodies found in AD. F-actin accumulation
and the formation of actin-rich rods correlated with the
degree of Tau-induced neuronal degeneration. Decreasing
F-actin levels reduced neurotoxicity in the retina of hTau
transgenic flies. This indicated that F-actin mediated hTau
neurotoxicity [66]. In addition, whereas hTauE14-induced
retinal toxicity was clearly modified by genetically modulat-
ing the actin cytoskeleton, the hTauAP-induced rough eye was
not enhanced by coexpressing actin. This showed that actin
changes occur downstream of hTau phosphorylation [66].
3.2.4. Tau and the Larval Neuromuscular Junction (NMJ). It
has been shown that overexpression of dTau, 0N3R hTau,
0N4R hTau, and hTauV337M in larval motor neurons causes
morphological disruption of NMJs characterized by satellite
boutons [40, 43, 67]. In 0N3R hTau-expressing motor neu-
rons, this is associated with abnormal endo/exocytosis char-
acterized by decreased evoked synaptic potentials following
high frequency stimulation [67]. The authors suggested that
this may be due to a reduction in axonal transport of mito-
chondria resulting in a reduction of functional mitochondria
in the presynaptic terminal [67]. No axonal transport defects
were observed in hTauV337M-expressing larval motor neurons
but in this model, abnormally shaped NMJs were associated
with loss of acetylated alpha-tubulin [43]. The authors
suggested that disruption of the cytoskeleton network in
presynaptic nerve terminals could constitute early events in
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the pathological process leading to synaptic dysfunction in
hTauV337M pathology.
3.3. Degradation of Tau. Dysfunction of protein degradation
may favor accumulation of toxic Tau species. Several studies
in Drosophila have analyzed Tau degradation. Endogenous
dTau was first described as being not degraded by the
proteasome pathway [68] although high-molecular-weight
forms of hyperphosphorylated hTau were shown to be
degraded by the proteasome [43]. Hsp70/Hsp90-organizing
protein homolog (Hop), a scaﬀold protein for chaperones,
has been identified as a suppressor of 2N4R hTau toxicity
and has been proposed to facilitate clearance of hTau via
the Ubiquitin-Proteasome System (UPS) [42]. Recently,
nicotinamide mononucleotide (NAD) adenylyl transferase
(NMNAT), a protein that has both NAD synthase and chap-
erone function, was shown to interact with phosphorylated
hTau oligomers in vivo and promote the ubiquitination
and clearance of toxic hTau species [53]. In contrast,
other chaperones, DnaJ-1, Csp, and Hsc70Cb, have been
identified unexpectedly as enhancers of hTauV337M toxicity
[43]. Despite the cytosolic subcellular localization of Tau,
expression of hTauWT, hTauR406W, and hTauE14 in Drosophila
brain triggers the unfolded protein response (UPR), a cell
response that handles excess misfolded proteins in the
secretory pathway causing endoplasmic reticulum (ER) stress
[69]. Mild ER stress is protective in retinal degeneration [70].
The UPR similarly protected against tau neurotoxicity [69].
Alternative degradation processes to the ubiquitin-
proteasome system include proteases and the autophagy-
lysosomal pathway. Calpain A and B have been shown to
cleave Tau and generate a toxic 17 kDa Tau fragment [30].
Mutations that disrupt endogenous calpain A or calpain
B activity or expression of a calpain-resistant form of Tau
hTauK44Q/R230Q in transgenic flies abrogated Tau toxicity in
vivo [30]. The puromycin-sensitive aminopeptidase (PSA)
has also been described as a modifier of Tau toxicity but
as a suppressor [22]. Although the original study described
that PSA digests directly Tau in vitro [22, 71], this idea
has been challenged more recently [72]. As shown in a
Drosophila polyQ disease model, the protective eﬀects of PSA
may instead be mediated through activation of autophagy
[73]. Several components related to the autophagy-lysosomal
pathway, Atg6, Vha14, Vha44, white, brown, rosy, dynein
light chain 2, benchwarmer/spinster, and cathepsinD, have
been identified as modifiers of Tau toxicity in Drosophila
[31, 42, 43, 46, 62]. Loss-of-function mutations of bench-
warmer/spinster, white, brown, and cathepsinD are associated
with enlarged lysosomes and enhanced hTau toxicity [31,
46, 62]. Loss of cathepsinD is also associated with caspase
activation and generation of a C-terminally truncated form
of hTau, which is more toxic and less soluble [31]. This
suggests that caspase cleavage of Tau may be a molecular
mechanism through which lysosomal dysfunction and neu-
rodegeneration are causally linked in Tauopathies.
3.4. Cell Death Pathways Associated with Tau Toxicity. Many
studies have detected markers of apoptosis, such as TUNEL-
positive staining, activated cleaved caspase 3, cleaved PARP,
and abnormal accumulation of lamin in hTau-expressing
tissue [7, 25, 29, 50, 53, 54, 66, 69]. Components of
the apoptotic pathway, such as dIAP1 and FEM-1, were
identified as modifiers of TauV337M toxicity [41]. In addition,
overexpression of dIAP1, dIAP2, and the baculovirus caspase
inhibitor p35 partially rescued the hTau-mediated rough eye
phenotype [7]. These results strongly support a role for
apoptosis in Tau-induced neurodegeneration in Drosophila.
The pathways that activate apoptosis upon Tau toxicity have
not been described yet. The study of cathepsinD mutant
showed that lysosomal dysfunction could trigger caspase
activation in fly Tau models [31]. Reactivation of the cell
cycle downstream of Tau phosphorylation has also been
shown to precede apoptosis in postmitotic neurons [29].
Fly brains overexpressing hTauR406W stained positive for the
cell cycle markers PCNA and PH3. Inhibition and activa-
tion of the cell cycle, respectively, reduced and increased
Tau toxicity but did not aﬀect Tau phosphorylation. This
indicated that cell cycle activation is a mediator of Tau
toxicity acting downstream of Tau phosphorylation. This
was confirmed by the use of the phosphomimetic hTauE14,
which induced increased cell cycle marker staining and
toxicity in comparison with hTauWT. The link between
Tau phosphorylation and cell cycle activation was shown
to be mediated by the TOR (Target of Rapamycin kinase)
pathway [29]. Furthermore, oxidative stress has been shown
to enhance Tau-induced cell cycle activation and toxicity
[54]. Genetic or pharmacological inhibition and induction
of oxidative stress reduced and increased hTauR406W toxicity.
Oxidative stress did not act by altering Tau phosphorylation
but enhanced cell-cycle activation [54].
3.5. Cell Signaling Pathways Modulating Tau Toxicity. Several
cell signaling pathways have been shown to modulate Tau
toxicity but the exact contribution of each pathway and their
interactions remain to be clarified and confirmed.
3.5.1. The Wingless(Wg)/Wnt Pathway. Sgg/GSK3β, one of
the major Tau kinases, belongs to the Wingless(Wg)/Wnt
pathway. GSK3β increased hTau phosphorylation, induced
hTau aggregation, and increased hTau toxicity [7]. In the
Wg/Wnt pathway, Sgg/GSK3β inhibits armadillo/β-catenin,
the downstream eﬀector with TCF.Whereas one could expect
that inhibition of armadillo and dTCF also contributed to
GSK3β-enhanced hTau toxicity, loss of armadillo and dTCF
rescued hTau rough eye phenotype whereas misexpression
enhanced it. This showed that (1) GSK3β does not exert
its primary eﬀect via the canonical Wg pathway but, rather,
via direct hTau hyperphosphorylation. (2) The Wg pathway
contributes to hTau toxicity, possibly through a function
in apoptotic cell death in degeneration associated with
hTau [7]. However, mimicking the Wg signaling pathway
by coexpression of dishevelled, an upstream component of
the pathway, with hTauWT reduces Tau phosphorylation and
Tau toxicity [48]. Therefore, the Wg pathway seems to be
involved in Tau pathology but the role of each component
of the pathway remains to be clarified.
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3.5.2. The Mitogen-Activated Protein Kinase (MAPK) Path-
ways. Several members of the MAPK family have been
involved in modulating hTau toxicity. From the cell stress
response pathway, the stress kinase Hemipterous(Hep)/JNK
was identified as an enhancer of the hTauV337M-induced
rough eye phenotype [41]. Overexpression of Hep/JNK also
exacerbated 0N4R hTauWT toxicity without aﬀecting the
phospho-deficient hTauAP, which suggested that Hep/JNK-
induced increased hTau toxicity is mediated through hTau
phosphorylation [27]. This mechanism has been involved in
the stress-inducing nonlethal reduction of axonal transport
[52]. Hep/JNK activation has also been detected upon oxida-
tive stress and the extent of Hep/JNK activation correlated
with the degree of hTau-induced neurodegeneration [54].
In this model, oxidative stress acted not to promote hTau
phosphorylation but to enhance hTau-induced cell cycle acti-
vation [54]. Recently, a genetic screen for modifiers of 2N4R
hTau toxicity identified components of the Extracellular
Regulated Kinase (ERK)/MAPK and p38/MAPK pathways
[42]. Loss-of-function alleles of ksr and Neuroglian (Nrg),
both of which promote ERK signaling, suppressed hTau
toxicity, suggesting that reducing ERK activity is beneficial.
Overexpression of Mekk1, a MAP3K that leads to the
phosphorylation and activation of p38/MAPK, was found
to strongly enhance hTau toxicity. Cross-talk between these
signaling pathways was shown and may also include interac-
tions with the GSK3β signaling pathway [42]. Interestingly,
in this study, some results suggested that hTau could have
a signaling function and be able to regulate its own kinases.
In addition, overexpression of 2N4R hTauS11A was previously
shown to increase the activated form of GSK-3β (Sgg Y214)
in comparison with 2N4R hTauWT [23]. As suggested by
Ambegaokar and coworkers, if Tau has the ability to regulate
its own kinases, and if this regulation is phosphorylation-
dependent, this would broaden our understanding of the role
of Tau phosphorylation, which to date has been primarily
associated with reduced microtubule-binding aﬃnity [42].
3.5.3. The TOR Pathway. It has been shown that the TOR
pathway links phosphorylated hTau to a toxic cell cycle
activation in postmitotic neurons [29]. Overexpression of
hTauR406W upregulated S6K phosphorylation, the target of
TOR kinase. Pharmacological or genetic inhibition of TOR
reduced hTauR406W- and hTauV337M-associated toxicity. The
TOR-induced increase in Tau toxicity was suppressed by
inhibiting cell cycle activation.
3.5.4. The DNA Repair Pathway. Recently, kinases from the
DNA repair pathway have been involved in a toxic phos-
phorylation of Tau [28]. It has been shown that the
Drosophila DNA damage-activated Checkpoint kinase2
(Chk2) phosphorylates hTau at Ser262 and enhances hTau
toxicity [28]. In addition, the DNA repair response was
increased by Aβ42 [74]. It is thus possible that the DNA
repair pathway induced by Aβ triggers Tau phosphorylation
and toxicity in the pathogenesis of AD.
3.5.5. The Janus Kinase (JAK)/Signal Transducer and Acti-
vator of Transcription (STAT) Pathway in Glia. In glia, the
JAK/STAT signaling pathway has been shown to be protective
against Tauopathy [50]. Expression of 0N4R hTau in glial
cells using the repo driver resulted in aged-dependent
hTau phosphorylation, hTau aggregation, formation of hTau
tangles and glial, and neuronal cell death. These phenotypes
were associated with a progressive loss of JAK/STAT sig-
naling. In addition, inhibiting or activating the JAK/STAT
signaling pathway in glia enhanced and suppressed cell death
in fly brain expressing hTau in glia [50]. The protective eﬀect
of the JAK/STAT pathway would occur downstream of Tau
phosphorylation as modulating the JAK/STAT pathway did
not change hTau phosphorylation [50].
3.6. Tau and APP/Aβ. HumanAβ42 andAppl, theDrosophila
ortholog of APP, have been shown to synergistically increase
Tau toxicity in Drosophila. Coexpression of bTau and Appl
under the ApplG1a driver synergistically induced axonal
transport defects in larval motor neurons, lethality at the
pharate adult stage, and a juvenile phenotype at the adult
stage [51]. Aβ42 expression strongly increased the rough eye
phenotype of hTau-expressing flies, as well as vacuolization
and the number of TUNEL-positive cells in the brain
[66]. Aβ42 coexpression also exacerbated Tau-mediated
disruption of axonal transport and synaptic structures,
leading to locomotor defects and reduced lifespan [48]. This
interaction shows thatDrosophila is a relevant model for AD.
Furthermore, studies in Drosophila gained insight into the
synergistic link between Aβ42 and Tau. Double-transgenic
flies coexpressing Aβ42 and either hTauAP or hTauE14, the
phospho-deficient and phosphomimetic hTau constructs,
showed no clear changes in retinal toxicity, suggesting that
the interaction between Aβ42 and hTau requires intact
Ser/Thr phosphorylation sites on Tau [66]. Coexpression
of hTau and Aβ42 increased hTau phosphorylation and
treatment of flies coexpressing hTau and Aβ42 with LiCl
suppressing the exacerbating eﬀect of Aβ42 [48]. This
suggests that GSK3β may be involved in the mechanism
by which Aβ42 and hTau interact, potentially through
hTau phosphorylation, to cause neuronal dysfunction [48].
Another mechanism has been proposed and involved the
Checkpoint kinase2 (Chk2) from the DNA repair pathway
[28, 74]. Coexpression of Aβ42 and hTau resulted in
increased hTau phosphorylation at several sites including
Ser262 and increased hTau toxicity. Mutating Ser262 to Ala
prevented hTau phosphorylation at this site and alleviated
Aβ42-induced Tau toxicity [74]. Ser262 is a target site of
the DNA damage-activated kinase Chk2 [28]. A number
of genes involved in the DNA repair pathway like Chk2
are increased in Aβ42 fly brains, and the induction of a
DNA repair response is protective against Aβ42 toxicity [74].
These results suggest that activation of DNA repair pathways
is protective against Aβ42 toxicity but may trigger hTau
phosphorylation and toxicity in AD pathology [74].
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3.7. Cell- and Isoform-Specificity of Tau Toxicity and Dys-
function. Discrepancies between studies suggest that mech-
anisms of Tau toxicity may be diﬀerent depending on cell-
types and Tau isoforms. A striking example comes from
the phosphomimetic and phospho-deficient Tau forms (see
Section 3.1). The phosphomimetic hTauE14 is strongly toxic
in the developing eye and in the mushroom body neurob-
lasts, in which the phospho-deficient hTauAP is not [24, 27,
29, 66], The opposite is true for vesicular motion in motor
neuron axons, neurohormone release, and animal survival
[49]. This is probably due to the state of diﬀerentiation of
the Tau-expressing neurons and the critical role of axonal
transport in these neurons. It was also shown that the
phosphorylation status and stability of Tau depend on the
subneuronal population in which Tau is expressed [75].
Besides cell-type specificity, hTau isoforms, FTD-related
hTau mutant forms, and Tau orthologs seem to have toxic
specificities despite common properties. The Skoulakis lab
has compared the toxicity of diﬀerent Tau isoforms in the
embryonic neuroblasts that generate the mushroom body
neurons, and the functional consequence on learning ability
in the adult flies [24]. They observed that expression of
0N4R and 2N4R hTau neuroblasts strongly aﬀected the
development of mushroom body neuroblasts leading to
the loss of mushroom bodies in the adult. Expression of
the FTD-related 0N4R hTauR406W and hTauV337M were
mildly toxic, whereas dTau, bTau, and 0N3R hTau were
not toxic. By comparing bTau and hTau sequences, they
identified two phosphorylation sites, Ser238 and Thr245,
which were specific to hTau. Mutation to alanine of these
sites fully suppressed hTau toxicity in mushroom bodies
neuroblasts [24]. Hence they were able to determine the
diﬀerence between bTau and hTau that is responsible for
their specific eﬀects in mushroom bodies neuroblasts. Other
examples of isoform specificity have been reported outside
the mushroom bodies. In motor neurons, hTauV337M did not
alter axonal transport in comparison with hTauWT but rather
aﬀected NMJ morphology [43]. Overexpression of either
dTau or hTau in the retina resulted in a similar rough eye
phenotype. However, coexpression of PAR-1 with dTau led
to lethality, whereas coexpression of PAR-1 with 0N4R hTau
had little eﬀect on the rough eye phenotype [39] and Par-1
coexpression increased 2N4R hTau toxicity in the eye [23].
The origin of the diﬀerences between these isoforms still
need to be explored. It has to be noted that possible genetic
interactions between ectopic hTau and endogenous dTau
should also be considered. Endogenous dTau expression has
been shown tomodulate bristle loss in the fly notum induced
by hTauWT [47]. The level of endogenous dTau expression
may participate in the cell-type specificity.
The work on the diﬀerent isoforms led the Skoulakis
lab to highlight the distinction between Tau toxicity and
Tau dysfunction (for reviews on this subject [76, 77]).
Whereas expression of 0N4R hTau and 2N4R hTau was
toxic and induced loss of mushroom bodies, expression
of bTau and dTau did not aﬀect the structure of the
mushroom bodies but aﬀected cognitive function [24].
Other phenotypes reported by other group are also more
related to toxicity or dysfunction. Eye roughness, lethality,
and decreased lifespan represent toxicity, whereas some
axonal transport, behavioural, or synaptic defects represent
dysfunction and were reported without toxicity [55]. The
next question will be to understand what regulates Tau
toxicity and Tau dysfunction. Drosophila has already given
some cues. Phosphorylation of Tau may be a good candidate.
Phosphorylation of Ser238 and Thr245 has been shown
to be responsible for hTau toxicity in mushroom bodies
neuroblasts [24]. Phosphorylation of Tau by PAR-1 has been
shown to be toxic in the eye [25], whereas phosphorylation of
Tau by GSK-3β seemed to reducemicrotubule binding rather
than be toxic and thus be related to dysfunction [23].
4. Genetic Screens in Drosophila: Perspectives
4.1. Forward Genetic Screens. To date, three forward genetic
screens for hTau modifiers have been published, all using
the hTau-associated rough eye as a readout for toxicity
[41–43]. The first two screens reported were highly similar
in design. Both screens were performed using the FTD-
associated hTauV337M mutant form of Tau and both screens
screened transposon insertions inducing misexpression [41,
43]. The transposon insertions, P{EP} and P{Mae-UAS-
.6.11}, can induce both gain- and loss-of-function pheno-
types, depending on the orientation of the insertion and the
presence of a GAL4 driver. Although the screens were highly
similar in design, the outcomes were considerably diﬀerent
likely because of diﬀerences in the screened transposon
collections. The screen by Shulman and Feany identified
kinases and phosphatases as most represented interactors
[41]. Among these, genes previously shown to aﬀect hTau
phosphorylation were found to modify the rough eye
phenotype. They identified par-1, the Drosophila homolog
of MARK as a suppressor of hTau toxicity. Furthermore,
two regulatory subunits of the known tau phosphatases,
PP1 and PP2A, were identified. In the category of the
kinases and phosphatases, string and twine were also found.
Both are phosphatases, and when overexpressed, suppress
Tau toxicity. This suggests that string and twine might
dephosphorylate tau and hence reduce toxicity. Additionally,
thread and CG9025 were identified. Both are inhibitors of
apoptosis, and the eﬀect of the transposon insertions is
as expected. If apoptosis inhibition is enhanced, the hTau
rough eye phenotype is suppressed. Other interactors hinted
a role for the cytoskeleton; overexpression of orbit, dfxr1,
and cheerio aggravated the tau-induced rough eye. The last
category overlaps with the findings of Blard and colleagues in
their very similar screen setup [43]. They identified cheerio,
Chd64, jaguar, and paxillin as enhancers. Remarkably, all
four of these genes are linked to the actin cytoskeleton.
Cheerio, also identified in the screen of Shulman and Feany,
encodes the Drosophila homolog of filamin. Filamins play an
important role in stabilizing and cross-linking filamentous
actin. A loss-of-function insertion in Chd64, the homolog
of mammalian transgelin-3, was found to enhance the tau
phenotype. In mammals, transgelin-3 was shown to colo-
calize with filamentous actin and α-tubulin, but also with
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Tau itself and MAP2. Jaguar was found to be homologous
to mammalian class VI Myosins, which are motor proteins
who transport their cargo towards the actin minus ends
[43]. Paxillin is a regulator of the Rho family GTPases,
Rac and Rho, which regulate actin cytoskeletal dynamics.
Other interactors identified in the screen included following
transcriptional regulators, CG33097, dumpy, and nab, but
also several transporters (1.28, vha44, ATPα) were identified.
The most exhaustive screen was recently published by
Ambegaokar and Jackson [42]. They screened two diﬀerent
P-element insertion collections. In addition to the EY
collection, which can induce both gain- and loss-of-function
eﬀects, this group for the first time screened a loss-of-
function collection consisting of 920 genomically mapped
lethal P-elements. In total, 1905 lines were screened and 37
modifiers of tau toxicity were identified. To exclude suppres-
sors that act on general apoptosis, each of the suppressors
was tested for inhibition of apoptosis by crossing them to
flies eye specifically overexpressing an inducer of apoptosis,
hid. The modifiers were then tested for eﬀects on the Tau
phosphorylation state. No consistent eﬀects were observed
among enhancers or suppressors. To quantify the eﬀects on
eye morphology, volume calculations were performed on
eyes of both enhancers and suppressors. The authors could
show that for all suppressors eye volume was increased, the
opposite was shown for the enhancers. Using the software
tool “Endeavour-highfly,” the investigators constructed a
network that extrapolates the findings and suggests new
pathways, cellular processes, and genes that might also
be involved in pathology. A network with the predicted
associations with statistical predictions P < 0.001 shows an
interesting role for RNA processing, lysosomal degradation
pathways, and, as expected, kinases and phosphatases. Five
of the in silico predicted genes were tested for their ability to
modify tau pathology in vivo. Both Tom34, a mitochondrial
protein, and Csul, a protein involved in RNA traﬃcking,
enhanced Tau pathology when gene function is reduced.
Overexpression of both genes could induce a substantial
rescue. A gene involved in RNA catabolism, armi, enhanced
Tau pathology in both loss-of-function and gain-of-function
approaches. Upf1and Tom20, involved in, respectively, RNA
catabolism and mitochondrial function, did not exert an
eﬀect on external eye morphology of flies overexpressing
hTau. This shows that the applied software prediction tool is
able to successfully identify genetic interactors of hTau, based
on results of a forward genetic screen.
4.2. Integration of Mammalian Genome-Wide High-Through-
put Experiments with Functional Validation in Drosophila.
Genome-wide high-throughput experiments such as genetic
genome-wide association studies (GWAS) and transcrip-
tomics have emerged during the last years as powerful
strategies to identify novel biological disease pathways.
However, given the vast amount of novel data generated in
these experiments and the fact that the function of many
of the identified genes or loci are not known, the biological
interpretation of these studies is diﬃcult. Recently, two very
interesting strategies tackling this problem were published.
The first study combines transcriptome analysis of mice
overexpressing Tau with functional validation in Drosophila
[22]. The second study starts with target identification in an
AD GWAS study, followed by validation in the fly [78]. In
both studies, Drosophila plays a central role in the functional
validation of targets found in mice or patients.
Karsten and colleagues analyzed transcriptomes of diﬀer-
ent brain regions of mice overexpressing the most common
FTD-associated mutant hTauP301L. These mice phenocopy
major pathological hallmarks of tauopathy including neu-
rodegeneration in the spinal cord and cortex. Neurodegener-
ation becomes apparent when the mice reach 7 to 9 months
of age but transcriptome analysis was performed at 6 months
of age when no major pathological phenotypes are present,
but low amounts of phosphorylated Tau can already be
detected. In total, 31 probe sets were found to be diﬀerentially
regulated in Tau mice compared to wild-type controls. An
interesting hit was the puromycin-sensitive aminopeptidase
(PSA) for which no neuroprotective role had previously been
suggested. To further investigate the role of PSA and other
genes, mutant alleles of the Drosophila homologs were tested
in a fly tau model. Loss of-function of PSA enhanced while
overexpression suppressed Tau toxicity. To further validate
PSA as a causal gene in neuroprotection, PSA abundance was
evaluated in both FTD patients and controls. Interestingly,
in both patients and controls, PSA expression was fivefold
higher in the cerebellum than in the cortex and a significant
increase in PSA was found in FTD patients compared to
controls [37].
Recently, the first study combining an AD GWAS study
with functional validation in Drosophila was published [33].
The study started with a GWAS on an autopsy cohort
of 227 individuals who were nondemented at recruitment.
All individuals were yearly evaluated clinically. The GWAS
identified 22 gene loci suggestive of being associated with
AD (P < 10−3). Of these 22 candidate genes identified, 19
genes had a clear homolog in Drosophila. In the second step,
these genes were tested in a fly model that uses the Tau-
induced rough eye as a read-out. Using a transgenic RNAi
approach, each of these 19 genes were knocked down in
flies overexpressing hTauV337M. If fly strains were available,
overexpression of the identified candidate genes was also
tested. Six genes, when knocked down, displayed a clear
genetic interaction with Tau, B-spec, fne,Glut1, hs6st, dlg, and
slit. For three of them, the opposite interaction was observed
with overexpression lines. When combined with statistically
more powerful GWAS datasets, functional validation of
GWAS hits using Tau and Aβ toxicity readouts in Drosophila
will likely be more powerful and informative.
5. Conclusion
In this paper, we have attempted to give an overview of the
many technical possibilities the Drosophila system oﬀers to
study the molecular, cellular, and physiological mechanisms
by which Tau causes neuronal degeneration and dysfunction.
The available studies reveal that Tau is involved in a wide
range of cellular and biochemical processes. Regarding the
role of phosphorylation of Tau in neuronal degeneration,
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studies in Drosophila suggest that this link is highly complex
and possibly less important than generally accepted. The
most innovating results from Drosophila have and will con-
tinue to come from (1) unbiased high-throughput forward
genetic screens that identify modifiers of Tau neurotoxicity
and (2) studies that address the normal function the
dTau gene. Finally, linking unbiased Drosophila to human
genetics will likely identify important molecular mechanisms
involved in Tau-mediated neuronal degeneration.
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